The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
We expect the global biodefense market to exhibit a CAGR of 7.2% during 2022-2027.
The growing number of terrorist attacks, along with rising cross-border conflicts, are some of the key factors driving the global biodefense market.
Sudden outbreak of the COVID-19 pandemic has positively influenced the demand for medical measures and threat detection procedures, such as biodefense.
Based on the vaccine type, the global biodefense market has been bifurcated into anthrax, smallpox, botulism, and others. Currently, anthrax holds the majority of the total market share.
Based on the end-user, the global biodefense market can be segmented into hospitals and clinics, ambulatory care centers, and others. Among these, hospitals and clinics exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America dominates the global market.
Some of the major players in the global biodefense market include Achaogen Inc., Alnylam Pharmaceuticals Inc., Altimmune Inc. (PharmAthene Inc.), Bavarian Nordic A/S, Cleveland BioLabs Inc., Dynavax Technologies Corporation, Dynport Vaccine Company LLC (General Dynamics Corporation), Elusys Therapeutics Inc., Emergent Biosolutions Inc., Ichor Medical Systems Inc., Ology Bioservices Inc., SIGA Technologies, Inc., etc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at